{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:47:40Z","timestamp":1770425260558,"version":"3.49.0"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017480","name":"Chang Bing Show Chwan Memorial Hospital","doi-asserted-by":"crossref","award":["MRD-114001"],"award-info":[{"award-number":["MRD-114001"]}],"id":[{"id":"10.13039\/501100017480","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Patients with colorectal cancer (CRC) have varying responses to 5-fluorouracil (5-FU) treatment, particularly reduced-dose regimens. Inflammatory and tumor-associated serum biomarkers, such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125, may refine prognostic assessment. However, their combined performance in patients with CRC receiving reduced-dose 5-FU remains understudied. This retrospective study evaluated the prognostic value of multiple biomarkers in these patients, aiming to identify optimal combinations for personalized therapeutic strategies and improved clinical outcomes. Methods: Data (2017\u20132023) on patients\u2019 clinicopathological characteristics and pretreatment serum biomarker levels were collected from a medical center in central Taiwan. Dose classification followed institutional standards. Reduced-dose chemotherapy was confirmed from patients\u2019 medical records. Intergroup comparisons, receiver operating characteristic curve analysis, logistic regression, Cox proportional hazards modeling, and survival analysis were performed. Furthermore, a multivariate prognostic nomogram was constructed. Results: The study cohort comprised 95 patients receiving reduced-dose 5-FU. Univariate analyses highlighted cigarette smoking, advanced stage, poor tumor differentiation, and elevated pretreatment CEA level as significant predictors of mortality. Multivariate analysis indicated tumor differentiation grade and pretreatment CEA level as significant independent predictors. Cancer antigen 125, CEA, and CA19-9 exhibited robust discriminatory performance. The multivariate nomogram exhibited acceptable discrimination. Conclusions: Tumor differentiation, disease stage, and pretreatment CEA level emerged as independent predictors of overall survival in patients with CRC receiving reduced-dose 5-FU. Serum biomarkers, particularly CEA and CA19-9, may be included in comprehensive prognostic models alongside clinicopathological characteristics. The validated prognostic nomogram may support personalized risk stratification and individualized dose-adjusted chemotherapy.<\/jats:p>","DOI":"10.3390\/jcm15010071","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:22:27Z","timestamp":1766578947000},"page":"71","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Factors and Biomarker Performance in Patients with Colorectal Cancer Receiving Reduced-Dose 5-Fluorouracil Therapy: A Retrospective Cohort Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Mei-Wen","family":"Chen","sequence":"first","affiliation":[{"name":"Cancer Administration and Coordination Center, Chang Bing Show Chwan Memorial Hospital, Changhua 505, Taiwan"},{"name":"Department of Information Management, National Open University, New Taipei 247, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Jim","family":"Ou","sequence":"additional","affiliation":[{"name":"Cancer Administration and Coordination Center, Chang Bing Show Chwan Memorial Hospital, Changhua 505, Taiwan"},{"name":"Department of Colon and Rectal Surgery, Chang Bing Show Chwan Memorial Hospital, Changhua 505, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Shyong","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua 505, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"ref_1","unstructured":"International Agency for Research on Cancer (2025, August 25). IARC Marks Colorectal Cancer Awareness Month 2025. Available online: https:\/\/www.iarc.who.int\/news-events\/iarc-marks-colorectal-cancer-awareness-month-2025\/."},{"key":"ref_2","first-page":"E499","article-title":"Global Disparities in Colorectal Cancer: Unveiling the Present Landscape of Incidence and Mortality Rates, Analyzing Geographical Variances, and Assessing the Human Development Index","volume":"65","author":"Darmadi","year":"2024","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_3","unstructured":"Ministry of Health and Welfare, Department of Statistics (D.o.S) (2025, August 31). Statistics of Leading Causes of Death in Taiwan, 2025, Available online: https:\/\/dep.mohw.gov.tw\/DOS\/lp-5069-113.html."},{"key":"ref_4","unstructured":"Health Promotion Administration, Ministry of Health and Welfare (M.o.H.a.W.) (2025, August 25). Taiwan Cancer Registry, Available online: https:\/\/www.hpa.gov.tw\/EngPages\/Detail.aspx?nodeid=1061&pid=6071."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000526827","article-title":"Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion","volume":"68","author":"Khatib","year":"2023","journal-title":"Chemotherapy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","article-title":"Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes","volume":"101","author":"Saif","year":"2009","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","article-title":"Therapeutic drug monitoring of 5-fluorouracil","volume":"78","author":"Lee","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/carcin\/bgt288","article-title":"Circulating C-reactive protein and colorectal cancer risk: A report from the Shanghai Men\u2019s Health Study","volume":"34","author":"Wu","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bjc.2015.87","article-title":"Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: The relationship to patient survival, tumour biology and local lymphocytic response to tumour","volume":"113","author":"Pine","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"80700","DOI":"10.18632\/oncotarget.13029","article-title":"The CEA-\/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells","volume":"7","author":"Yan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lakemeyer, L., Sander, S., Wittau, M., Henne-Bruns, D., Kornmann, M., and Lemke, J. (2021). Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer. Diseases, 9.","DOI":"10.3390\/diseases9010021"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/TUB-200069","article-title":"CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242","volume":"43","author":"Mustonen","year":"2021","journal-title":"Tumour Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1159\/000495824","article-title":"Clinicopathologic Features and Prognostic Factors in Alpha-Fetoprotein-Producing Colorectal Cancer: Analysis of 78 Cases","volume":"51","author":"Feng","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ma, Z., Yang, S., Yang, Y., Luo, J., Zhou, Y., and Yang, H. (2023). Development and validation of prediction models for the prognosis of colon cancer with lung metastases: A population-based cohort study. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1073360"},{"key":"ref_16","first-page":"1156","article-title":"Prognostic factors for survival in colorectal cancer patients","volume":"93","author":"Maneechavakajorn","year":"2010","journal-title":"J. Med. Assoc. Thai"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li\u0219cu, H.D., Verga, N., Atasiei, D.I., Badiu, D.C., Dumitru, A.V., Ultimescu, F., Pavel, C., Stefan, R.E., Manole, D.C., and Ionescu, A.I. (2024). Biomarkers in Colorectal Cancer: Actual and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111535"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhang, W., Li, Y., Jia, J., Yang, Y., Hu, Y., Wang, Y., and Wang, J. (2025). Prediction of 5-year postoperative survival and analysis of key prognostic factors in stage III colorectal cancer patients using novel machine learning algorithms. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1604386"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17621","DOI":"10.1038\/s41598-025-02674-9","article-title":"Association between prediagnostic risk factors and survival after colorectal cancer diagnosis in Golesten cohort study","volume":"15","author":"Yadegar","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_20","first-page":"e68667","article-title":"Prognostic Significance of Tumor and Inflammatory Markers in Disease-Free and Overall Survival Duration in Colonic Adenocarcinoma Patients","volume":"16","author":"Tutan","year":"2024","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3892\/ol.2025.15281","article-title":"Preoperative C-reactive protein-albumin-lymphocyte index predicts survival outcomes in patients with stage I-III colorectal cancer: A retrospective cohort study","volume":"30","author":"Li","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cotan, H.T., Emilescu, R.A., Iaciu, C.I., Orlov-Slavu, C.M., Olaru, M.C., Popa, A.M., Jinga, M., Nitipir, C., Schreiner, O.D., and Ciobanu, R.C. (2024). Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review. Cancers, 16.","DOI":"10.3390\/cancers16233928"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17588359251356581","DOI":"10.1177\/17588359251356581","article-title":"Interim C-reactive protein levels predict the prognosis of patients with metastatic colorectal cancer receiving immunotherapy: A retrospective cohort study","volume":"17","author":"Fu","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_24","first-page":"69","article-title":"Update on the management of elderly patients with colorectal cancer","volume":"26","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, J., Zhu, H., Liu, W., Miao, J., Mao, Y., and Li, Q. (2025). Prognostic and predictive molecular biomarkers in colorectal cancer. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1532924"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e5177","DOI":"10.1097\/MD.0000000000005177","article-title":"Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Han, T., Deng, S., Xia, D., Jin, K., and Mei, C. (2025). Clinical value of cystatin S in patients with colorectal cancer chemotherapy. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1640646"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/71\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T05:14:34Z","timestamp":1766639674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15010071"],"URL":"https:\/\/doi.org\/10.3390\/jcm15010071","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}